Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
View Patent ↗The invention relates to salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical composition for use, e.g., in treatment of airway disorders.
1. Hydrate form of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride.
2. Crystalline hydrate form of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride.
3. A form of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride selected from the group consisting of a hydrate form, a crystalline form and a crystalline form of a hydrate form.
4. A pharmaceutical composition comprising the hydrate form of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride according to claim 1 together with pharmaceutical excipients and/or vehicles.
5. A pharmaceutical composition comprising the crystalline hydrate form of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride according to claim 2 together with pharmaceutical excipients and/or vehicles.
6. A pharmaceutical composition comprising (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride in a form according to claim 3 together with pharmaceutical excipients and/or vehicles.
7. A method of treating diabetes mellitus in a patient comprising administering to said patient a therapeutically effective amount of the hydrate form of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride according to claim 1 .
8. A method of treating diabetes mellitus in a patient comprising administering to said patient a therapeutically effective amount of the crystalline hydrate form of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride according to claim 2 .
9. A method of treating diabetes mellitus in a patient comprising administering to said patient a therapeutically effective amount of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol hydrochloride in a form according to claim 3 .